Statins Are Associated With Increased Insulin Resistance and Secretion

Author:

Abbasi Fahim1234ORCID,Lamendola Cindy123,Harris Chelsea S.13,Harris Vander123,Tsai Ming-Shian254ORCID,Tripathi Pragya12,Abbas Fakhar123,Reaven Gerald M.123,Reaven Peter D.6,Snyder Michael P.254,Kim Sun H.347ORCID,Knowles Joshua W.12348ORCID

Affiliation:

1. Division of Cardiovascular Medicine (F. Abbasi, C.L., C.S.H., V.H., P.T., F. Abbas, G.M.R., J.W.K.), Stanford University, CA.

2. Cardiovascular Institute (F. Abbasi, C.L., C.S.H., V.H., M.-S.T., P.T., F. Abbas, G.M.R., M.P.S., J.W.K.), Stanford University, CA.

3. Department of Medicine (F. Abbasi, C.L., C.S.H., V.H., F.A., G.M.R., S.H.K., J.W.K.), Stanford University, CA.

4. Stanford Diabetes Research Center (F.A., M.-S.T., M.P.S., S.H.K., J.W.K.), Stanford University, CA.

5. Department of Genetics (M.-S.T., M.P.S.), Stanford University, CA.

6. University of Arizona and Phoenix VA Health Care System (P.D.R.).

7. Division of Endocrinology, Gerontology and Metabolism (S.H.K.), Stanford University, CA.

8. Stanford Prevention Research Center (J.W.K.), Stanford University, CA.

Abstract

Objective: Statin treatment reduces the risk of atherosclerotic cardiovascular disease but is associated with a modest increased risk of type 2 diabetes, especially in those with insulin resistance or prediabetes. Our objective was to determine the physiological mechanism for the increased type 2 diabetes risk. Approach and Results: We conducted an open-label clinical trial of atorvastatin 40 mg daily in adults without known atherosclerotic cardiovascular disease or type 2 diabetes at baseline. The co-primary outcomes were changes at 10 weeks versus baseline in insulin resistance as assessed by steady-state plasma glucose during the insulin suppression test and insulin secretion as assessed by insulin secretion rate area under the curve (ISR AUC ) during the graded-glucose infusion test. Secondary outcomes included glucose and insulin, both fasting and during oral glucose tolerance test. Of 75 participants who enrolled, 71 completed the study (median age 61 years, 37% women, 65% non-Hispanic White, median body mass index, 27.8 kg/m 2 ). Atorvastatin reduced LDL (low-density lipoprotein)-cholesterol (median decrease 53%, P <0.001) but did not change body weight. Compared with baseline, atorvastatin increased insulin resistance (steady-state plasma glucose) by a median of 8% ( P =0.01) and insulin secretion (ISR AUC ) by a median of 9% ( P <0.001). There were small increases in oral glucose tolerance test glucose AUC (median increase, 0.05%; P =0.03) and fasting insulin (median increase, 7%; P =0.01). Conclusions: In individuals without type 2 diabetes, high-intensity atorvastatin for 10 weeks increases insulin resistance and insulin secretion. Over time, the risk of new-onset diabetes with statin use may increase in individuals who become more insulin resistant but are unable to maintain compensatory increases in insulin secretion. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02437084. Graphic Abstract: A graphic abstract is available for this article.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3